EUVIMEDEUVIMED entdecken
Vergleichsstudie

A Post-Market Economic Evaluation of Bortezomib, Lenalidomide and Dexamethasone Versus Pre-funding Standard of Care for Newly Diagnosed Multiple Myeloma Using Registry Data

Adam Irving, Dennis Petrie, Anthony Harris, Laura Fanning, Erica M Wood, Elizabeth Moore, Cameron Wellard, Neil Waters, Bradley Augustson, Gordon Cook, Francesca Gay, Georgia McCaughan und 3 weitere

PharmacoEconomics · 2026

DOI: 10.1007/s40273-025-01554-4 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift PharmacoEconomics, 2026. Verfasst von Adam Irving und 14 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Health Economics, Monash Business School, Monash University, Melbourne, VIC, Australia. adam.irving@monash.edu. Hauptthemen laut MEDLINE: Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols, Standard of Care. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Medical Research Future Fund (AU), National Health and Medical Research Council (AU).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Health technology assessments traditionally rely on clinical trial data, leaving uncertainties about real-world cost effectiveness. This post-market economic evaluation used registry data to estimate the real-world cost effectiveness of bortezomib, lenalidomide and dexamethasone (VRd) versus standard of care as it existed prior to VRd funding for newly diagnosed, transplant eligible and ineligible multiple myeloma, as subsidised by the Australian government in 2019. METHODS: We conducted the economic evaluation from the perspective of the Australian healthcare system using the EpiMAP Myeloma model, a discrete event simulation model powered by risk equations based on data from the Australia & New Zealand Myeloma and Related Diseases Registry. This approach captured individual patient heterogeneity and treatment pathways through up to nine lines of therapy. We assessed differences in quality-adjusted life-years and costs over a lifetime horizon, discounting both at the standard Australian rate of 5% per annum. Costs were valued in 2025 Australian dollars and non-parametric bootstrapping was used to quantify parameter uncertainty. RESULTS: Brtezomib, lenalidomide and dexamethasone was associated with 0.16 incremental quality-adjusted life-years (95% confidence interval [CI] 0.10, 0.21) and A$16K incremental costs (95% CI A$12K, A$120K). Improved response to therapy with VRd was predicted to marginally increase receipt of autologous stem cell transplantation by 1.1% (95% CI 0.6, 1.7), significantly increase receipt of maintenance therapy by 13.8% (95% CI 10.4, 17.3) and marginally decrease the proportion of patients progressing to subsequent lines. None of the bootstrap iterations fell below the traditional A$50K/quality-adjusted life-year threshold. CONCLUSIONS: The 2019 decision to universally fund VRd for newly diagnosed multiple myeloma did not result in a cost-effective allocation of healthcare resources when judged against the traditional A$50K/quality-adjusted life-year threshold. Our findings provide nuanced insights into the real-world cost effectiveness of VRd, highlighting how post-market evaluations can inform refinement of funding decisions for complex therapeutic interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntineoplastic Combined Chemotherapy ProtocolsStandard of CareHumansLenalidomideDexamethasoneBortezomibCost-Benefit AnalysisQuality-Adjusted Life YearsAustraliaRegistriesTechnology Assessment, Biomedical

Substanzen

LenalidomideDexamethasoneBortezomib

Autor:innen und Institutionen

  • Centre for Health Economics, Monash Business School, Monash University, Melbourne, VIC, Australia. adam.irving@monash.edu.
  • Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia. adam.irving@monash.edu.
  • Centre for Health Economics, Monash Business School, Monash University, Melbourne, VIC, Australia.
  • Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
  • Sir Charles Gairdner Hospital, Nedlands, Perth, WA, Australia.
  • Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.

Förderung

  • Medical Research Future Fund (AU)
  • National Health and Medical Research Council (AU)

Zitieren

APA

Irving, A., Petrie, D., Harris, A., Fanning, L., Wood, E. M., Moore, E., Wellard, C., Waters, N., Augustson, B., Cook, G., Gay, F., McCaughan, G., Mollee, P., Spencer, A., & McQuilten, Z. K. (2026). A Post-Market Economic Evaluation of Bortezomib, Lenalidomide and Dexamethasone Versus Pre-funding Standard of Care for Newly Diagnosed Multiple Myeloma Using Registry Data. PharmacoEconomics. https://doi.org/10.1007/s40273-025-01554-4

Vancouver

Irving A, Petrie D, Harris A, Fanning L, Wood EM, Moore E, et al. A Post-Market Economic Evaluation of Bortezomib, Lenalidomide and Dexamethasone Versus Pre-funding Standard of Care for Newly Diagnosed Multiple Myeloma Using Registry Data. PharmacoEconomics. 2026. doi:10.1007/s40273-025-01554-4

BibTeX
@article{Irving2026,
  author = {Irving, Adam and Petrie, Dennis and Harris, Anthony and Fanning, Laura and Wood, Erica M and Moore, Elizabeth and Wellard, Cameron and Waters, Neil and Augustson, Bradley and Cook, Gordon and Gay, Francesca and McCaughan, Georgia and Mollee, Peter and Spencer, Andrew and McQuilten, Zoe K},
  title = {A Post-Market Economic Evaluation of Bortezomib, Lenalidomide and Dexamethasone Versus Pre-funding Standard of Care for Newly Diagnosed Multiple Myeloma Using Registry Data},
  journal = {PharmacoEconomics},
  year = {2026},
  doi = {10.1007/s40273-025-01554-4}
}
Kostenlos starten →